Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher Registry
Gaucher disease is a lysosomal storage disorder caused by a deficiency of the enzyme acid β-glucosidase. The most prevalent mutant genotype in type I Gaucher disease, N370S/N370S, is commonly thought to confer a mild phenotype presenting in adulthood. To characterize a subset of more severely affected N370S homozygotes, we assessed the phenotypes at or near the time of diagnosis of all N370S homozygotes with available data enrolled in the International Collaborative Gaucher Group Gaucher Registry. N370S compound heterozygotes were analyzed for comparison, as they are expected to present with a more severe phenotype. Of 798 N370S homozygotes and 1,278 N370S compound heterozygotes identified, 32% (251/788) and 65% (820/1269), respectively, were diagnosed before age 20 years. At diagnosis, N370S homozygotes as compared to N370S compound heterozygotes had the following clinical characteristics: irreversible skeletal lesions 17% (34/198) for N370S homozygotes versus 26% (76/290) for N370S compound heterozygotes; anaemia 18% (59/327) versus 29% (145/494); thrombocytopenia 52% (170/327) versus 62% (281/453); hepatomegaly 44% (83/190) versus 72% (141/195); splenomegaly 73% (142/194) versus 91% (178/195); and osteopenia or osteoporosis 48.6% (34/70) versus 51% (25/49). Some N370S homozygotes exhibited more severe clinical manifestations: 9% (29/327) had severe thrombocytopenia; 3% (5/190) had severe hepatomegaly; 11% (22/194) had severe splenomegaly; 7% (18/255) reported bone crises; 11% (8/70) had osteoporosis. In conclusion, N370S homozygosity does not consistently confer a mild, adult-onset phenotype. Gaucher disease patients with the N370S/N370S genotype exhibit a high degree of phenotypic heterogeneity and some may be at risk for early disease onset and severe clinical manifestations.
- Agmon V, Cherbu S, Dagan A, Grace M, Grabowski GA, Gatt S (1993) Synthesis and use of novel fluorescent glycosphingolipids for estimating beta-glucosidase activity in vitro in the absence of detergents and subtyping Gaucher disease variants following administration into intact cells. Biochim Biophys Acta 1170: 72–79.PubMedGoogle Scholar
- Beutler E, Grabowski GA (2006) Gaucher Disease. In Scriver CR, Beaudet AL, Sly WS, et al, eds. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 3635–3668.Google Scholar
- Bornstein P, McKinney CE, LaMarca ME, et al (1995) Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease. Proc Natl Acad Sci U S A 92: 4547–4551. doi:10.1073/pnas.92.10.4547.PubMedCrossRefGoogle Scholar
- Grabowski G, Kolodny EH, Weinreb N (2006) Gaucher disease: phenotypic and genetic variation. In Scriver CR, Beaudet AL, Valle D, Sly WS, Vogelstein B, Kinzler KW, and Childs B, eds. The Online Metabolic and Molecular Basis of Inherited Metabolic Disease. New York: McGraw-Hill, Available at: http://genetics.accessmedicine.com/mmbid/public/co_contents/toc_part16.html.
- Nielsen KB, Sorensen S, Cartegni L, et al (2007) Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 80: 416–432.PubMedCrossRefGoogle Scholar
- Tayebi N, Stern H, Dymarskaia I, Herman J, Sidransky E (1996) 55-base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet 66: 316–319. doi:10.1002/(SICI)1096-8628(19961218)66:3<316::AID-AJMG15>3.0.CO;2-P.PubMedCrossRefGoogle Scholar